NAIROBI, Kenya — HIV injections given every eight weeks worked about as well as daily pills at keeping the virus under control in African adults who had struggled to take tablets on time, according to a trial published in the New England Journal of Medicine on 15 October 2026. The IMPALA trial, conducted in Kenya, South Africa and Uganda, found that 91.0 per cent of people on the long-acting injections had their virus suppressed at 48 weeks, compared with 89.2 per cent on daily pills — a result that met the study's goal of showing the injections were no worse than the pills.
Illustration: A nurse preparing a long-acting injection at a bright modern health clinic in Africa, with a patient seated calmly.
What Happened
IMPALA — short for IMProving HIV-1 Control in Africa using Long-Acting Antiretrovirals — was a randomised, open-label Phase 3b trial. It enrolled 540 adults living with HIV whose virus was already suppressed but who had a history of difficulty taking daily tablets on time or staying in care. Participants were randomly assigned either to continue daily oral treatment based on dolutegravir, or to switch to long-acting injections of cabotegravir plus rilpivirine, given into the muscle every eight weeks.
Of the 537 people included in the main analysis, the virus was below 50 copies per millilitre of blood at week 48 in 244 of 268 people (91.0 per cent) on injections and 240 of 269 people (89.2 per cent) on pills. That met the trial's noninferiority goal: the injections did not have to beat the pills, only to be shown not meaningfully worse. The authors note that about one million people in eastern and southern Africa who take HIV pills still do not have the virus suppressed, often because of the difficulty of daily adherence — the exact problem the injections are designed to solve.
The results were not unqualified. Confirmed treatment failure — two consecutive blood tests at 200 copies or higher — occurred in five people (1.9 per cent) on injections and in none on pills. According to aidsmap's reporting of the trial, drug-resistance testing was possible in four of those five cases, all showing high-level cabotegravir resistance and three showing high-level rilpivirine resistance, though all five were able to resuppress the virus on an oral regimen. Serious side effects were reported in 11 of 271 people (4.1 per cent) on injections and 8 of 269 (3.0 per cent) on pills.
Background
HIV treatment has been transformed over the past three decades from a death sentence into a manageable chronic condition — but only for people who can stay on treatment every day. Daily pills work, yet real life gets in the way: travel, stigma, clinic distance, stock-outs and simple forgetfulness all interrupt adherence, and each interruption gives the virus a chance to rebound. Long-acting injections, given every two months at a clinic, remove the daily burden and replace it with a scheduled visit.
The combination used in IMPALA pairs two drugs that attack HIV in different ways: cabotegravir, an integrase inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Both have been formulated as long-acting injections, and the regimen is already used in some high-income settings. But evidence in African populations — where most people with HIV live, where viral subtypes differ, and where adherence challenges are shaped by different health systems — has been thinner. IMPALA was designed specifically to fill that gap, recruiting across three countries and including people whose previous control of the virus had been suboptimal.
The trial was funded by Johnson & Johnson, which makes rilpivirine and sells the injectable combination with ViiV Healthcare's cabotegravir, and the study authors note that drug-resistance testing was not done at the start of the trial. Those caveats matter for how the results are read: this is a 48-week trial in 540 people, not a long-term answer, and it cannot settle questions about safety over many years or about cost and access in the health systems that would need to deliver the injections.
Illustration: Scientists in a laboratory studying blood samples and viral research data on screens.
Why It Matters
The result matters because it addresses the single biggest practical obstacle in HIV care: staying on treatment. A regimen that works only when taken perfectly is of limited use to the people who struggle most with daily pills, and IMPALA deliberately recruited exactly those people — adults whose virus was suppressed but who had a history of poor adherence or disengagement from care. Showing that injections can match pills in that group, rather than in an idealised population, is what makes the finding useful to clinics rather than merely interesting to researchers.
It also matters for the broader goal of ending HIV as a public health threat. Suppressed virus means not only better health for the individual but also that the virus cannot be transmitted to others — the principle known as undetectable equals untransmittable. Every person whose treatment fails because daily pills did not fit their life is a person at risk of illness and of passing the virus on. An alternative that fits more lives could therefore close part of the gap between the treatment that exists and the treatment that actually gets taken.
At the same time, the five treatment failures are a genuine caution. Resistance to both injected drugs developed in some of those cases, which limits future options for those individuals and underlines why injections are not a simple replacement for pills: they require reliable clinic attendance every eight weeks, monitoring, and a plan for what happens if a visit is missed. The trial's authors and commentators agree that the injections are an additional option, not a superior one — and certainly not a cure. Both treatments only keep HIV under control while they are used.
What Happens Next
The next questions are practical ones: cost, supply and delivery. Long-acting injections must be given in clinics by trained staff, kept in a cold chain where required, and scheduled reliably — demands that strain health systems in exactly the places where adherence support is weakest. Policymakers and funders will weigh the IMPALA results against those realities, and against the price of the injectable combination compared with cheap generic daily pills, before deciding how widely to offer it.
Longer follow-up from the trial, which is designed to run for 24 months, will also show whether the 48-week results hold and whether resistance or side effects accumulate over time. For now, the message for patients is a measured one: if daily pills are hard to sustain, an injection every eight weeks is now a supported alternative in the populations studied — but it is a choice to discuss with a clinician, not a decision to make alone.
This article provides general health information only and is not medical advice. Anyone considering a change to HIV treatment should discuss it with their own clinician.
Illustration: Community health workers walking through a village in East Africa carrying medical supply kits in warm morning light.
Sponsored: explore today's featured sponsored offers
FAQ
What did the IMPALA trial test?
IMPALA compared long-acting injections of cabotegravir plus rilpivirine, given every eight weeks, with daily dolutegravir-based pills in 540 adults with HIV in Kenya, South Africa and Uganda.
What were the results at 48 weeks?
The virus was suppressed below 50 copies per millilitre in 91.0 per cent of people on injections and 89.2 per cent on pills, meeting the trial's goal of showing the injections were no worse than the pills.
Who took part in the trial?
Adults whose HIV was already suppressed but who had a history of difficulty taking daily tablets on time or staying in care — the group most likely to benefit from an alternative to daily pills.
Is this a cure for HIV?
No. Both the injections and the pills only keep HIV under control while they are used. There is no cure for HIV today.
What are the caveats?
Five people on injections had confirmed treatment failure, some developing drug resistance; the trial lasted 48 weeks in 540 people, so it cannot answer questions about longer-term safety, cost or delivery at scale.
Sources
- New England Journal of Medicine, "Long-Acting HIV Therapy in African Adults with Adherence Challenges (IMPALA)," 15 October 2026, via PubMed.
- aidsmap, "Injectable HIV treatment works for people with poor HIV control in Africa," October 2026.
- Cure Checker, "HIV Injections Every 8 Weeks Matched Daily Pills in an African Trial," 16 October 2026.
- ClinicalTrials.gov, IMPALA trial registration NCT05546242.
Comments
Post a Comment